Tiara™ Transcatheter Mitral Valve Replacement Study

NCT ID: NCT03039855

Last Updated: 2025-09-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

157 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-03-08

Study Completion Date

2024-08-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the safety and performance of the Neovasc Tiara Mitral Transcatheter Heart Valve with the Tiara Transapical Delivery System.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The TIARA-II study is an international, multicenter, single-arm, prospective, safety and performance clinical study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mitral Valve Regurgitation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment

Transcatheter mitral valve replacement with the TIARA valve and transapical delivery system

Group Type EXPERIMENTAL

TIARA valve and transapical delivery system

Intervention Type DEVICE

Transcatheter mitral valve replacement

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TIARA valve and transapical delivery system

Transcatheter mitral valve replacement

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

TIARA Mitral Transcatheter Heart Valve, TIARA Transapical Delivery System

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Severe mitral regurgitation
* High surgical risk for open mitral valve surgery
* Subject meets anatomical eligibility criteria

Exclusion Criteria

* Deemed too frail by objective frailty assessments
* Previous cardiac procedures: any mitral valve replacement surgery and cardiac transplant
* Unsuitable cardiac structure
* Clinically significant untreated Coronary Artery Disease (CAD)
* Subjects on chronic dialysis
* Pregnant or planning pregnancy within next 12 months
* Documented bleeding or coagulation disorders
* Active infections requiring antibiotic therapy
* Subjects with a life expectancy less than 12 months
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shockwave Medical, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kerckhoff Klinik Herzzentrum-Herzchirurgie

Bad Nauheim, , Germany

Site Status

Herz- und Diabeteszentrum NRW

Bad Oeynhausen, , Germany

Site Status

Schüchtermann-Klinik

Bad Rothenfelde, , Germany

Site Status

Deutches Herzzentrum Berlin

Berlin, , Germany

Site Status

Immanuel Klinikum Bernau und Herzzentrum Brandenburg

Bernau, , Germany

Site Status

St.-Johannes-Hospital, Klinik für Innere Medizin I

Dortmund, , Germany

Site Status

Universitätsklinikum Halle

Halle, , Germany

Site Status

Universitasklinikum Hamburg-Eppendorf

Hamburg, , Germany

Site Status

Herzzentrum Leipzig

Leipzig, , Germany

Site Status

Herz-Kreislauf-Zentrum Klinikum Hersfeld Rotenburg

Rotenburg an der Fulda, , Germany

Site Status

Sana Herzchirurgie Stuttgart GmbH

Stuttgart, , Germany

Site Status

Tel Aviv Medical Center

Tel Aviv, , Israel

Site Status

Fondazione Policlinico Universitario A. Gemelli - Università Cattolica del Sacro Cuore.

Roma, RM, Italy

Site Status

Fondazione Toscana 'Gabriele Monasterio'

Massa, , Italy

Site Status

Ospedale San Raffaele

Milan, , Italy

Site Status

IRCCS Policlinico San Donato

San Donato Milanese, , Italy

Site Status

St. Antonius Hospital

Nieuwegein, , Netherlands

Site Status

Hospital Clinico San Carlos

Madrid, , Spain

Site Status

Edinburgh Heart Centre Royal Infirmary

Edinburgh, , United Kingdom

Site Status

King's College Hospital

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany Israel Italy Netherlands Spain United Kingdom

Related Links

Access external resources that provide additional context or updates about the study.

http://www.neovasc.com

Company website with product information

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

047-CPT-003

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The REACT-ICD Trial
NCT02439424 UNKNOWN PHASE1/PHASE2